This article is interesting. It basically shows that the experts get this wrong at least 50% of the time. If you get a path report back saying a cellular blue nevus with atypical features then treat it as a melanoma and excise appropriately. IMCC
Atypical Cellular Blue Nevi (Cellular Blue Nevi With Atypical Features): Lack of Consensus for Diagnosis and Distinction From Cellular Blue Nevi and Malignant Melanoma ("Malignant Blue Nevus").
Original Articles
American Journal of Surgical Pathology. 32(1):36-44, January 2008.
Barnhill, Raymond L. MD *; Argenyi, Zsolt MD +; Berwick, Marianne PhD ++; Duray, Paul H. MD [S]; Erickson, Lori MD [//]; Guitart, Joan MD [P]; Horenstein, Marcello G. MD [sharp]; Lowe, Lori MD **; Messina, Jane MD ++; Paine, Susan MPH ++; Piepkorn, Michael W. MD, PhD +; Prieto, Victor MD, PhD ++++; Rabkin, Michael S. MD, PhD [S][S]; Schmidt, Birgitta MD [//][//]; Selim, Angelica MD [P][P]; Shea, Chris R. MD [sharp][sharp]; Trotter, Martin J. MD, PhD ***
Abstract:
The distinction of cellular blue nevi (CBN) with atypical features ["atypical" CBN (ACBN)] from conventional CBN and malignant melanomas related to or derived from CBN remains a difficult problem. Here, we report on the diagnosis of various cellular blue melanocytic neoplasms by 14 dermatopathologists who routinely examine melanocytic lesions. Three parameters were assessed: (1) for between rater analyses, we calculated interobserver agreement by the [kappa] statistic (regardless of whether the diagnosis was correct). (2) For each individual lesion, we reported whether a majority agreement (>50%) was reached and, if so, whether the majority agreed with the gold standard diagnosis, derived from standardized histopathologic criteria for melanoma, definitive outcome such as metastatic event or death of disease, or disease-free follow-up for >=4 years. (3) For the individual pathologists, we calculated sensitivity and specificity for each type of lesion. The study set included 26 melanocytic lesions: (1) 6 malignant melanomas developing in or with attributes of CBN; (2) 11 CBN with atypical features and indeterminate biologic potential (ACBN); (3) 8 conventional CBN; and (4) 1 common BN. The [kappa] values for interrater agreement varied from 0.52 (95% confidence interval 0.45, 0.58) for melanoma to 0.02 (0.05, 0.08) for ACBN and 0.20 (0.13, 0.28) for CBN. The [kappa] for all lesions was 0.25 (0.22, 0.28). The pathologists' sensitivities were 68.6% (61.0%, 76.1%) for melanoma, 33.1% (21.0%, 45.2%) for ACBN, and 44.6% (29.0%, 60.3%) for CBN. The specificities were 65.7% (55.8%, 75.6%) for melanoma, 84.7% (77.3%, 92.2%) for ACBN, and 89.9% (82.7%, 97.1%) for CBN. Overall, greater than 50% of the pathologists agreed and were correct in their diagnosis 38.5% (10 lesions) of the time. There was a majority agreement, but with an incorrect diagnosis, another 26.9% (7 lesions) of the time. Six of the 7 majority agreements with an incorrect diagnosis were for ACBN lesions. In summary, the results of our study indicate that there is substantial confusion and disagreement among experienced histopathologists about the definitions and biologic nature of cellular blue melanocytic neoplasms particularly those thought to have atypical features ("atypical" CBN).
